AMRI: Summary for Albany Molecular Research, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 3:08am EST - Canadian Markets open in 6 hours and 22 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Albany Molecular Research Inc. (AMRI)

On Feb 9: 8.46 USD 0.00 (0.00%)

MORE ON AMRI

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Albany Molecular Research, Inc. (NasdaqNM:AMRI) Delayed quote data

Last Trade:	8.46 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	8.46
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	8.00

Day's Range:	N/A - N/A
52wk Range:	7.31 - 11.31
Volume:	0
Avg Vol (3m):	79,355.6
Market Cap:	267.70M
P/E (ttm):	46.74
EPS (ttm):	0.18
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add AMRI to Portfolio

Download Data

HEADLINES

•	AMRI reports $19M net loss in 4Q
	at bizjournals.com (Mon, Feb 8)

•	ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
	EDGAR Online (Mon, Feb 8)

•	AMRI Announces Fourth Quarter 2009 Results
	Business Wire (Mon, Feb 8)

•	AMRI CFO to Present at UBS 20th Annual Global Healthcare Services Conference
	Business Wire (Tue, Feb 2)

•	AMRI to Announce Fourth Quarter Results
	Business Wire (Mon, Feb 1)

•	Research And Development Expenditures In Diagnostic And Lab Equipment Sector Raises Capital Requirements: Will Acquisitions By Larger Health Care Companies Be The Result?
	Wall Street Transcript (Wed, Jan 27)

•	AMRI CFO to Present at Jefferies 2010 Global Healthcare Services Conference
	Business Wire (Tue, Jan 19)

•	AMRI Receives SafeBridge® Potent Compound Safety Certification
	Business Wire (Tue, Jan 19)

•	AMRI CEO to Present at 28th Annual J.P. Morgan Healthcare Conference
	Business Wire (Thu, Jan 7)

•	Bruno name stays put in Capital Region
	at bizjournals.com (Wed, Dec 9)

More Headlines for AMRI...

ANALYST

EPS Est (next year) (Dec-10) :	0.17
EPS Est (in 2 years) (Dec-11) :	N/A
Avg Rec (current)*:	3.0
PEG Ratio:	4.96

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States and Europe.

Full Company Profile

Add to Portfolio

Email to a Friend

•